Biocept to Launch Lung Cancer Test in Q4; Sees Ability to Monitor CTCs and ctDNA as Differentiator | GenomeWeb

This article has been updated from a previous version to more accurately characterize cell-free DNA (cfDNA) as circulating tumor DNA (ctDNA).

NEW YORK (GenomeWeb News) — In the wake of a February IPO that raised $19 million in gross proceeds, oncology diagnostics firm Biocept plans to launch its first "liquid biopsy" test with a molecular component by the end of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.